Neurocognition in NSCLC Patients Treated With Osimertinib or Osimertinib + WBI

Summary

This is a prospective, randomised, positive-controlled, study to assess the neurocognitive function of upfront Osimertinib compared to whole-brain irradiation (WBI) plus Osimertinib in EGFR-mutant (Ex 19Del and L858R) NSCLC patients with symptomatic brain metastases, as well as the efficacy and safety.

Timeline

Start

2021-04-07

Primary completion

2024-04-01

Completion

2025-10-31

Drugs

Indications